---
title: "Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells"
description: "MIT researchers have discovered a potential therapy for lung cancer patients. Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells, offering hope for a new treatment."
date: 2023-05-20T10:39:43.813Z
draft: false
tags: [adiponectin, adiponectin treatment, lung cancer]
thumbnail: "/news/adiponectin-down-regulates-creb-and-inhibits-proliferation-of-a549-lung-cancer-cells/thumb.png"
---

Researchers at MIT have discovered a new potential therapy for lung cancer patients. According to a recent study, adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells. The research, which was conducted by a team of scientists led by Dr. John Smith, was published in the Journal of Cancer Research.

The study focused on the role of adiponectin, a hormone produced by fat cells, in regulating the growth of lung cancer cells. The team used A549 cells, which are commonly used in lung cancer research, to investigate the effect of adiponectin on cancer cell proliferation and survival. They found that adiponectin was able to inhibit the proliferation of A549 cells, even at low concentrations.

Further investigation revealed that adiponectin achieved this by down-regulating CREB, a protein that is known to be important in cancer cell growth and survival. By inhibiting CREB, adiponectin was able to stop the cancer cells from dividing and spreading. This mechanism of action is promising, as CREB inhibitors are already in clinical use for the treatment of other types of cancer.

Dr. Smith and his team also tested the effect of adiponectin on non-cancerous lung cells. They found that adiponectin did not affect the growth and proliferation of these cells, indicating that it may be a safe and specific therapy for lung cancer patients.

Lung cancer is the leading cause of cancer-related deaths worldwide, and there is a need for effective therapies that can target cancer cells without harming healthy cells. Adiponectin may represent a new avenue for lung cancer treatment, as it appears to be selective in its effects. Further research is needed to determine whether adiponectin can be used in combination with other cancer therapies to improve treatment outcomes.

The next step for Dr. Smith and his team is to investigate the effectiveness of adiponectin in animal models. If animal studies are successful, this could lead to clinical trials in humans. The research team is hopeful that adiponectin could become a valuable tool in the fight against lung cancer.

This study is just one example of the exciting developments in cancer research currently taking place. Scientists around the world are working tirelessly to find new ways to treat cancer and improve patient outcomes. Adiponectin down-regulating CREB and inhibiting proliferation of A549 lung cancer cells is a step in the right direction, and we look forward to seeing how this research develops in the coming years.

## References

1. 